Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial
| LSTA Stock | USD 2.75 1.15 29.49% |
About 62% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lisata |
By Karen Roman Biopharma company Lisata Therapeutics, Inc. said it finished patient enrollment for the next stage of its CENDIFOX trial. The study will assess the safety and effects of combining certepetide, Lisatas cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated. By addressing the unmet medical needs
Read at finance.yahoo.com
 |
Lisata Therapeutics Fundamental Analysis
We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Lisata Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Lisata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.
Peers
Lisata Therapeutics Related Equities
| PULM | Pulmatrix | 12.77 | ||||
| IMNN | Imunon | 7.87 | ||||
| TPST | Tempest Therapeutics | 4.55 | ||||
| RZLT | Rezolute | 3.74 | ||||
| BPTH | Bio Path | 3.57 | ||||
| CADL | Candel Therapeutics | 3.22 | ||||
| LIXT | Lixte Biotechnology | 2.51 | ||||
| PTIX | Protagenic Therapeutics | 2.44 | ||||
| MBRX | Moleculin Biotech | 0.57 | ||||
| XOMAO | XOMA | 0.28 | ||||
| GLUE | Monte Rosa | 0.54 | ||||
| ANTX | AN2 Therapeutics | 0.79 |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |